← All indications
Arteritis
INFLAMMATION of any ARTERIES.
Subtype terms (5)
More specific conditions that are subtypes of Arteritis in the MeSH hierarchy.
- AIDS Arteritis, Central Nervous System
- Endarteritis
- Giant Cell Arteritis
32 drugs (27 approved, 5 experimental)
- Polyarteritis Nodosa
17 drugs (16 approved, 1 experimental)
- Takayasu Arteritis
27 drugs (24 approved, 3 experimental)
Drugs by status
Approved for this indication (1)
Phase 2 trials (1)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (5)
Organization Involved with Phase 3 Indications (25)
- Abbott
- AbbVie
- Regeneron
- Bristol-Myers Squibb
- Sanofi
- Chugai
- GlaxoSmithKline
- University of Pennsylvania
- University of Ottawa
- University of South Florida
- Utrecht University
- Chinese SLE Treatment And Research Group
- Tsinghua University
- University of Limoges
- University of Toulouse
- University of Paris
- Valenciennes Hospital Centre
- Canadian Institutes of Health Research (CIHR)
- Central Hospital Saint Quentin
- Dutch Health Care Insurance Board
- Rouen Normandy University
- University of Burgundy
- University of Picardie Jules Verne
- The Cleveland Clinic
- Chinese Academy of Medical Sciences
Organization Involved with Phase 2 Indications (17)
- Centocor
- Eli Lilly
- Novartis
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Seoul National University
- University of Rochester
- University of Bern
- Mayo Clinic
- University of Amsterdam
- CHNO des Quinze-Vingts
- Janssen Pharmaceutica NV
- Allergan PLC (2015)
- Assistance Publique - Hôpitaux de Paris
- Athera Biotechnologies AB
- Kiniksa Pharmaceuticals, Ltd.
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (5)